Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study
Abstract Background: The anticoagulant warfarin, which is administered as a racemic mixture of R - and S -enantiomers, has been reported to interact with other drugs, including some antiepileptics. Eslicarbazepine acetate (ESL) is a once-daily voltage-gated sodium channel blocker that has been devel...
Saved in:
| Published in | Clinical therapeutics Vol. 32; no. 1; pp. 179 - 192 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Bridgewater, NJ
EM Inc USA
2010
Elsevier Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Abstract Background: The anticoagulant warfarin, which is administered as a racemic mixture of R - and S -enantiomers, has been reported to interact with other drugs, including some antiepileptics. Eslicarbazepine acetate (ESL) is a once-daily voltage-gated sodium channel blocker that has been developed for the treatment of partial epilepsy and other indications. Objective: The aim of this work was to investigate whether multiple-dose administration of ESL had any effect on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers stabilized on warfarin at a subtherapeutic level. Methods: Subjects received ESL 1200 mg once daily for 8 days concomitantly with racemic warfarin, the dose of which had been individually optimized to a stable prothrombin international normalized ratio (INR) of 1.3 to 1.8 during a previous run-in phase (up to 21 days). Coadministration of ESL and warfarin was followed by a 7-day recovery period when warfarin was again administered alone. The effects of ESL on the steady-state pharmacokinetics of R - and S -warfarin and on the INR were assessed. For the R - and S -warfarin assay, blood sampling was to occur at stage 1 (run-in period), 3 days before starting ESL dosing; stage 2 (combined treatment period), on days 1 and 8 at predose and 0.5, 1, 2, 4, 6, 8, 12, 16, and 24 hours postdose, and on days 4, 6, and 7 at predose; and stage 3 (after the combined treatment period) on days 3, 5, and 7 predose, and on day 8 at 24 hours after the final warfarin dose. For determination of INR, blood sampling was to occur at stage 2 on days 1, 2, 4, 6, 7, and 8 at predose; and at stage 3 on days 1, 3, 5, and 7 at predose and on day 8 at 24 hours after the final warfarin dose. For the assay of the racemic mixture of the S - and the R -enantiomers (eslicarbazepine and R -licarbazepine), blood sampling was to occur at stage 2 on day 8 at predose and 0.5, 1, 2, 4, 6, 8, 12, 16, and 24 hours postdose, and on days 2, 4, 6, and 7 at predose. Cmax and AUC0-t were defined as primary pharmacokinetic parameters. Tolerability was evaluated by monitoring adverse events, clinical laboratory safety tests, vital signs, and 12-lead ECG. Results: Of the 15 subjects enrolled, 13 (7 men and 6 women) completed the study. The mean (SD) age was 28.1 (7.3) years (range, 20–42 years), mean weight was 67.3 (10.7) kg (range, 54.0–84.4 kg), and 14 subjects (93.3%) were white. Reductions in S -warfarin Cmax (test:reference geometric means ratio [GMR] = 0.81 [90% CI, 0.76 to 0.86] and in S-warfarin AUCss (test:reference GMR = 0.77 [90% CI, 0.72 to 0.82]) were observed, without any clinically relevant changes in the INR. The mean INR was 1.45 (0.10) when warfarin was used alone in stage 1 (control) and 1.51 (0.25) when ESL was added to warfarin in stage 2. In relation to stage 1, a slight mean INR increase of 4.04% [90% CI, 1.03% to 9.12%] was reported in stage 2. In stage 3, following discontinuation of ESL administration, a change of −5.42% in the INR was found [90% CI, −8.85% to −1.98%]. ESL was not associated with any clinically relevant changes in R -warfarin pharmacokinetic parameters. No deaths, serious adverse events, or discontinuations due to adverse events were noted, and no clinically relevant findings were reported for the other safety variables. During the course of the study, 9 subjects (60%) reported a total of 32 adverse events. Catheter-site ecchymosis, venipuncturesite hematoma, dizziness, vasovagal reaction, and adhesive-tape allergy were the most common adverse events reported. During coadministration of ESL and warfarin, 7 subjects reported a total of 17 adverse events, of which 6 (epigastric discomfort, asthenia, dizziness, lipothymia, irritability, and macular rash) were considered possibly related to treatment; only lipothymia reached moderate intensity, and all symptoms subsided without sequelae after ESL was discontinued. Conclusions: In this short-term study in healthy subjects, coadministration of warfarin and ESL 1200 mg once daily was associated with a small, but statistically significant, reduction in systemic exposure to S-warfarin. There was no statistically significant effect on R-warfarin pharmacokinetics or on coagulation as measured by the INR. Protocol identifier: UFH/BIA-2093-108. |
|---|---|
| AbstractList | The anticoagulant warfarin, which is administered as a racemic mixture of R- and S-enantiomers, has been reported to interact with other drugs, including some antiepileptics. Eslicarbazepine acetate (ESL) is a once-daily voltage-gated sodium channel blocker that has been developed for the treatment of partial epilepsy and other indications.
The aim of this work was to investigate whether multiple-dose administration of ESL had any effect on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers stabilized on warfarin at a subtherapeutic level.
Subjects received ESL 1200 mg once daily for 8 days concomitantly with racemic warfarin, the dose of which had been individually optimized to a stable prothrombin international normalized ratio (INR) of 1.3 to 1.8 during a previous run-in phase (up to 21 days). Coadministration of ESL and warfarin was followed by a 7-day recovery period when warfarin was again administered alone. The effects of ESL on the steady-state pharmacokinetics of R- and S-warfarin and on the INR were assessed. For the R- and S-warfarin assay, blood sampling was to occur at stage 1 (run-in period), 3 days before starting ESL dosing; stage 2 (combined treatment period), on days 1 and 8 at predose and 0.5, 1, 2, 4, 6, 8, 12, 16, and 24 hours postdose, and on days 4, 6, and 7 at predose; and stage 3 (after the combined treatment period) on days 3, 5, and 7 predose, and on day 8 at 24 hours after the final warfarin dose. For determination of INR, blood sampling was to occur at stage 2 on days 1, 2, 4, 6, 7, and 8 at predose; and at stage 3 on days 1, 3, 5, and 7 at predose and on day 8 at 24 hours after the final warfarin dose. For the assay of the racemic mixture of the S- and the R-enantiomers (eslicarbazepine and R-licarbazepine), blood sampling was to occur at stage 2 on day 8 at predose and 0.5, 1, 2, 4, 6, 8, 12, 16, and 24 hours postdose, and on days 2, 4, 6, and 7 at predose. C(max) and AUC(0-t) were defined as primary pharmacokinetic parameters. Tolerability was evaluated by monitoring adverse events, clinical laboratory safety tests, vital signs, and 12-lead ECG.
Of the 15 subjects enrolled, 13 (7 men and 6 women) completed the study. The mean (SD) age was 28.1 (7.3) years (range, 20-42 years), mean weight was 67.3 (10.7) kg (range, 54.0-84.4 kg), and 14 subjects (93.3%) were white. Reductions in S-warfarin C(max) (test:reference geometric means ratio [GMR] = 0.81 [90% CI, 0.76 to 0.86] and in S-warfarin AUC(ss) (test:reference GMR = 0.77 [90% CI, 0.72 to 0.82]) were observed, without any clinically relevant changes in the INR. The mean INR was 1.45 (0.10) when warfarin was used alone in stage 1 (control) and 1.51 (0.25) when ESL was added to warfarin in stage 2. In relation to stage 1, a slight mean INR increase of 4.04% [90% CI, 1.03% to 9.12%] was reported in stage 2. In stage 3, following discontinuation of ESL administration, a change of -5.42% in the INR was found [90% CI, -8.85% to -1.98%]. ESL was not associated with any clinically relevant changes in R-warfarin pharmacokinetic parameters. No deaths, serious adverse events, or discontinuations due to adverse events were noted, and no clinically relevant findings were reported for the other safety variables. During the course of the study, 9 subjects (60%) reported a total of 32 adverse events. Catheter-site ecchymosis, venipuncturesite hematoma, dizziness, vasovagal reaction, and adhesive-tape allergy were the most common adverse events reported. During coadministration of ESL and warfarin, 7 subjects reported a total of 17 adverse events, of which 6 (epigastric discomfort, asthenia, dizziness, lipothymia, irritability, and macular rash) were considered possibly related to treatment; only lipothymia reached moderate intensity, and all symptoms subsided without sequelae after ESL was discontinued.
In this short-term study in healthy subjects, coadministration of warfarin and ESL 1200 mg once daily was associated with a small, but statistically significant, reduction in systemic exposure to S-warfarin. There was no statistically significant effect on R-warfarin pharmacokinetics or on coagulation as measured by the INR. Protocol identifier: UFH/BIA-2093-108. Background_ The anticoagulant warfarin, which is administered as a racemic mixture of R - and S -enantiomers, has been reported to interact with other drugs, including some antiepileptics. Eslicarbazepine acetate (ESL) is a once-daily voltage-gated sodium channel blocker that has been developed for the treatment of partial epilepsy and other indications. Objective_ The aim of this work was to investigate whether multiple-dose administration of ESL had any effect on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers stabilized on warfarin at a subtherapeutic level. Methods_ Subjects received ESL 1200 mg once daily for 8 days concomitantly with racemic warfarin, the dose of which had been individually optimized to a stable prothrombin international normalized ratio (INR) of 1.3 to 1.8 during a previous run-in phase (up to 21 days). Coadministration of ESL and warfarin was followed by a 7-day recovery period when warfarin was again administered alone. The effects of ESL on the steady-state pharmacokinetics of R - and S -warfarin and on the INR were assessed. For the R - and S -warfarin assay, blood sampling was to occur at stage 1 (run-in period), 3 days before starting ESL dosing; stage 2 (combined treatment period), on days 1 and 8 at predose and 0.5, 1, 2, 4, 6, 8, 12, 16, and 24 hours postdose, and on days 4, 6, and 7 at predose; and stage 3 (after the combined treatment period) on days 3, 5, and 7 predose, and on day 8 at 24 hours after the final warfarin dose. For determination of INR, blood sampling was to occur at stage 2 on days 1, 2, 4, 6, 7, and 8 at predose; and at stage 3 on days 1, 3, 5, and 7 at predose and on day 8 at 24 hours after the final warfarin dose. For the assay of the racemic mixture of the S - and the R -enantiomers (eslicarbazepine and R -licarbazepine), blood sampling was to occur at stage 2 on day 8 at predose and 0.5, 1, 2, 4, 6, 8, 12, 16, and 24 hours postdose, and on days 2, 4, 6, and 7 at predose. Cmax and AUC0-t were defined as primary pharmacokinetic parameters. Tolerability was evaluated by monitoring adverse events, clinical laboratory safety tests, vital signs, and 12-lead ECG. Results_ Of the 15 subjects enrolled, 13 (7 men and 6 women) completed the study. The mean (SD) age was 28.1 (7.3) years (range, 20-42 years), mean weight was 67.3 (10.7) kg (range, 54.0-84.4 kg), and 14 subjects (93.3%) were white. Reductions in S -warfarin Cmax (test:reference geometric means ratio [GMR] = 0.81 [90% CI, 0.76 to 0.86] and in S-warfarin AUCss (test:reference GMR = 0.77 [90% CI, 0.72 to 0.82]) were observed, without any clinically relevant changes in the INR. The mean INR was 1.45 (0.10) when warfarin was used alone in stage 1 (control) and 1.51 (0.25) when ESL was added to warfarin in stage 2. In relation to stage 1, a slight mean INR increase of 4.04% [90% CI, 1.03% to 9.12%] was reported in stage 2. In stage 3, following discontinuation of ESL administration, a change of -5.42% in the INR was found [90% CI, -8.85% to -1.98%]. ESL was not associated with any clinically relevant changes in R -warfarin pharmacokinetic parameters. No deaths, serious adverse events, or discontinuations due to adverse events were noted, and no clinically relevant findings were reported for the other safety variables. During the course of the study, 9 subjects (60%) reported a total of 32 adverse events. Catheter-site ecchymosis, venipuncturesite hematoma, dizziness, vasovagal reaction, and adhesive-tape allergy were the most common adverse events reported. During coadministration of ESL and warfarin, 7 subjects reported a total of 17 adverse events, of which 6 (epigastric discomfort, asthenia, dizziness, lipothymia, irritability, and macular rash) were considered possibly related to treatment; only lipothymia reached moderate intensity, and all symptoms subsided without sequelae after ESL was discontinued. Conclusions_ In this short-term study in healthy subjects, coadministration of warfarin and ESL 1200 mg once daily was associated with a small, but statistically significant, reduction in systemic exposure to S-warfarin. There was no statistically significant effect on R-warfarin pharmacokinetics or on coagulation as measured by the INR. Protocol identifier: UFH/BIA-2093-108. BACKGROUNDThe anticoagulant warfarin, which is administered as a racemic mixture of R- and S-enantiomers, has been reported to interact with other drugs, including some antiepileptics. Eslicarbazepine acetate (ESL) is a once-daily voltage-gated sodium channel blocker that has been developed for the treatment of partial epilepsy and other indications.OBJECTIVEThe aim of this work was to investigate whether multiple-dose administration of ESL had any effect on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers stabilized on warfarin at a subtherapeutic level.METHODSSubjects received ESL 1200 mg once daily for 8 days concomitantly with racemic warfarin, the dose of which had been individually optimized to a stable prothrombin international normalized ratio (INR) of 1.3 to 1.8 during a previous run-in phase (up to 21 days). Coadministration of ESL and warfarin was followed by a 7-day recovery period when warfarin was again administered alone. The effects of ESL on the steady-state pharmacokinetics of R- and S-warfarin and on the INR were assessed. For the R- and S-warfarin assay, blood sampling was to occur at stage 1 (run-in period), 3 days before starting ESL dosing; stage 2 (combined treatment period), on days 1 and 8 at predose and 0.5, 1, 2, 4, 6, 8, 12, 16, and 24 hours postdose, and on days 4, 6, and 7 at predose; and stage 3 (after the combined treatment period) on days 3, 5, and 7 predose, and on day 8 at 24 hours after the final warfarin dose. For determination of INR, blood sampling was to occur at stage 2 on days 1, 2, 4, 6, 7, and 8 at predose; and at stage 3 on days 1, 3, 5, and 7 at predose and on day 8 at 24 hours after the final warfarin dose. For the assay of the racemic mixture of the S- and the R-enantiomers (eslicarbazepine and R-licarbazepine), blood sampling was to occur at stage 2 on day 8 at predose and 0.5, 1, 2, 4, 6, 8, 12, 16, and 24 hours postdose, and on days 2, 4, 6, and 7 at predose. C(max) and AUC(0-t) were defined as primary pharmacokinetic parameters. Tolerability was evaluated by monitoring adverse events, clinical laboratory safety tests, vital signs, and 12-lead ECG.RESULTSOf the 15 subjects enrolled, 13 (7 men and 6 women) completed the study. The mean (SD) age was 28.1 (7.3) years (range, 20-42 years), mean weight was 67.3 (10.7) kg (range, 54.0-84.4 kg), and 14 subjects (93.3%) were white. Reductions in S-warfarin C(max) (test:reference geometric means ratio [GMR] = 0.81 [90% CI, 0.76 to 0.86] and in S-warfarin AUC(ss) (test:reference GMR = 0.77 [90% CI, 0.72 to 0.82]) were observed, without any clinically relevant changes in the INR. The mean INR was 1.45 (0.10) when warfarin was used alone in stage 1 (control) and 1.51 (0.25) when ESL was added to warfarin in stage 2. In relation to stage 1, a slight mean INR increase of 4.04% [90% CI, 1.03% to 9.12%] was reported in stage 2. In stage 3, following discontinuation of ESL administration, a change of -5.42% in the INR was found [90% CI, -8.85% to -1.98%]. ESL was not associated with any clinically relevant changes in R-warfarin pharmacokinetic parameters. No deaths, serious adverse events, or discontinuations due to adverse events were noted, and no clinically relevant findings were reported for the other safety variables. During the course of the study, 9 subjects (60%) reported a total of 32 adverse events. Catheter-site ecchymosis, venipuncturesite hematoma, dizziness, vasovagal reaction, and adhesive-tape allergy were the most common adverse events reported. During coadministration of ESL and warfarin, 7 subjects reported a total of 17 adverse events, of which 6 (epigastric discomfort, asthenia, dizziness, lipothymia, irritability, and macular rash) were considered possibly related to treatment; only lipothymia reached moderate intensity, and all symptoms subsided without sequelae after ESL was discontinued.CONCLUSIONSIn this short-term study in healthy subjects, coadministration of warfarin and ESL 1200 mg once daily was associated with a small, but statistically significant, reduction in systemic exposure to S-warfarin. There was no statistically significant effect on R-warfarin pharmacokinetics or on coagulation as measured by the INR. Protocol identifier: UFH/BIA-2093-108. Abstract Background: The anticoagulant warfarin, which is administered as a racemic mixture of R - and S -enantiomers, has been reported to interact with other drugs, including some antiepileptics. Eslicarbazepine acetate (ESL) is a once-daily voltage-gated sodium channel blocker that has been developed for the treatment of partial epilepsy and other indications. Objective: The aim of this work was to investigate whether multiple-dose administration of ESL had any effect on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers stabilized on warfarin at a subtherapeutic level. Methods: Subjects received ESL 1200 mg once daily for 8 days concomitantly with racemic warfarin, the dose of which had been individually optimized to a stable prothrombin international normalized ratio (INR) of 1.3 to 1.8 during a previous run-in phase (up to 21 days). Coadministration of ESL and warfarin was followed by a 7-day recovery period when warfarin was again administered alone. The effects of ESL on the steady-state pharmacokinetics of R - and S -warfarin and on the INR were assessed. For the R - and S -warfarin assay, blood sampling was to occur at stage 1 (run-in period), 3 days before starting ESL dosing; stage 2 (combined treatment period), on days 1 and 8 at predose and 0.5, 1, 2, 4, 6, 8, 12, 16, and 24 hours postdose, and on days 4, 6, and 7 at predose; and stage 3 (after the combined treatment period) on days 3, 5, and 7 predose, and on day 8 at 24 hours after the final warfarin dose. For determination of INR, blood sampling was to occur at stage 2 on days 1, 2, 4, 6, 7, and 8 at predose; and at stage 3 on days 1, 3, 5, and 7 at predose and on day 8 at 24 hours after the final warfarin dose. For the assay of the racemic mixture of the S - and the R -enantiomers (eslicarbazepine and R -licarbazepine), blood sampling was to occur at stage 2 on day 8 at predose and 0.5, 1, 2, 4, 6, 8, 12, 16, and 24 hours postdose, and on days 2, 4, 6, and 7 at predose. Cmax and AUC0-t were defined as primary pharmacokinetic parameters. Tolerability was evaluated by monitoring adverse events, clinical laboratory safety tests, vital signs, and 12-lead ECG. Results: Of the 15 subjects enrolled, 13 (7 men and 6 women) completed the study. The mean (SD) age was 28.1 (7.3) years (range, 20–42 years), mean weight was 67.3 (10.7) kg (range, 54.0–84.4 kg), and 14 subjects (93.3%) were white. Reductions in S -warfarin Cmax (test:reference geometric means ratio [GMR] = 0.81 [90% CI, 0.76 to 0.86] and in S-warfarin AUCss (test:reference GMR = 0.77 [90% CI, 0.72 to 0.82]) were observed, without any clinically relevant changes in the INR. The mean INR was 1.45 (0.10) when warfarin was used alone in stage 1 (control) and 1.51 (0.25) when ESL was added to warfarin in stage 2. In relation to stage 1, a slight mean INR increase of 4.04% [90% CI, 1.03% to 9.12%] was reported in stage 2. In stage 3, following discontinuation of ESL administration, a change of −5.42% in the INR was found [90% CI, −8.85% to −1.98%]. ESL was not associated with any clinically relevant changes in R -warfarin pharmacokinetic parameters. No deaths, serious adverse events, or discontinuations due to adverse events were noted, and no clinically relevant findings were reported for the other safety variables. During the course of the study, 9 subjects (60%) reported a total of 32 adverse events. Catheter-site ecchymosis, venipuncturesite hematoma, dizziness, vasovagal reaction, and adhesive-tape allergy were the most common adverse events reported. During coadministration of ESL and warfarin, 7 subjects reported a total of 17 adverse events, of which 6 (epigastric discomfort, asthenia, dizziness, lipothymia, irritability, and macular rash) were considered possibly related to treatment; only lipothymia reached moderate intensity, and all symptoms subsided without sequelae after ESL was discontinued. Conclusions: In this short-term study in healthy subjects, coadministration of warfarin and ESL 1200 mg once daily was associated with a small, but statistically significant, reduction in systemic exposure to S-warfarin. There was no statistically significant effect on R-warfarin pharmacokinetics or on coagulation as measured by the INR. Protocol identifier: UFH/BIA-2093-108. Background: The anticoagulant warfarin, which is administered as a racemic mixture of R- and S-enantiomers, has been reported to interact with other drugs, including some antiepileptics. Eslicarbazepine acetate (ESL) is a once-daily voltage-gated sodium channel blocker that has been developed for the treatment of partial epilepsy and other indications. Objective: The aim of this work was to investigate whether multiple-dose administration of ESL had any effect on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers stabilized on warfarin at a subtherapeutic level. Methods: Subjects received ESL 1200 mg once daily for 8 days concomitantly with racemic warfarin, the dose of which had been individually optimized to a stable prothrombin international normalized ratio (INR) of 1.3 to 1.8 during a previous run-in phase (up to 21 days). Coadministration of ESL and warfarin was followed by a 7-day recovery period when warfarin was again administered alone. The effects of ESL on the steady-state pharmacokinetics of R- and S-warfarin and on the INR were assessed. For the R- and S-warfarin assay, blood sampling was to occur at stage 1 (run-in period), 3 days before starting ESL dosing; stage 2 (combined treatment period), on days 1 and 8 at predose and 0.5, 1, 2, 4, 6, 8, 12, 16, and 24 hours postdose, and on days 4, 6, and 7 at predose; and stage 3 (after the combined treatment period) on days 3, 5, and 7 predose, and on day 8 at 24 hours after the final warfarin dose. For determination of INR, blood sampling was to occur at stage 2 on days 1, 2, 4, 6, 7, and 8 at predose; and at stage 3 on days 1, 3, 5, and 7 at predose and on day 8 at 24 hours after the final warfarin dose. For the assay of the racemic mixture of the S- and the R-enantiomers (eslicarbazepine and R-licarbazepine), blood sampling was to occur at stage 2 on day 8 at predose and 0.5, 1, 2, 4, 6, 8, 12, 16, and 24 hours postdose, and on days 2, 4, 6, and 7 at predose. C max and AUC 0-t were defined as primary pharmacokinetic parameters. Tolerability was evaluated by monitoring adverse events, clinical laboratory safety tests, vital signs, and 12-lead ECG. Results: Of the 15 subjects enrolled, 13 (7 men and 6 women) completed the study. The mean (SD) age was 28.1 (7.3) years (range, 20–42 years), mean weight was 67.3 (10.7) kg (range, 54.0–84.4 kg), and 14 subjects (93.3%) were white. Reductions in S-warfarin C max (test:reference geometric means ratio [GMR] = 0.81 [90% CI, 0.76 to 0.86] and in S-warfarin AUC ss (test:reference GMR = 0.77 [90% CI, 0.72 to 0.82]) were observed, without any clinically relevant changes in the INR. The mean INR was 1.45 (0.10) when warfarin was used alone in stage 1 (control) and 1.51 (0.25) when ESL was added to warfarin in stage 2. In relation to stage 1, a slight mean INR increase of 4.04% [90% CI, 1.03% to 9.12%] was reported in stage 2. In stage 3, following discontinuation of ESL administration, a change of −5.42% in the INR was found [90% CI, −8.85% to −1.98%]. ESL was not associated with any clinically relevant changes in R-warfarin pharmacokinetic parameters. No deaths, serious adverse events, or discontinuations due to adverse events were noted, and no clinically relevant findings were reported for the other safety variables. During the course of the study, 9 subjects (60%) reported a total of 32 adverse events. Catheter-site ecchymosis, venipuncturesite hematoma, dizziness, vasovagal reaction, and adhesive-tape allergy were the most common adverse events reported. During coadministration of ESL and warfarin, 7 subjects reported a total of 17 adverse events, of which 6 (epigastric discomfort, asthenia, dizziness, lipothymia, irritability, and macular rash) were considered possibly related to treatment; only lipothymia reached moderate intensity, and all symptoms subsided without sequelae after ESL was discontinued. Conclusions: In this short-term study in healthy subjects, coadministration of warfarin and ESL 1200 mg once daily was associated with a small, but statistically significant, reduction in systemic exposure to S-warfarin. There was no statistically significant effect on R-warfarin pharmacokinetics or on coagulation as measured by the INR. Protocol identifier: UFH/BIA-2093-108. |
| Author | Soares-da-Silva, Patricio, MD, PhD Almeida, Luis, MD, PhD, FFPM Maia, Joana, PharmD Falcão, Amilcar, PharmD, PhD Vaz-da-Silva, Manuel, MD, PhD Nunes, Teresa, MD Soares, Eva, BSc |
| Author_xml | – sequence: 1 fullname: Vaz-da-Silva, Manuel, MD, PhD – sequence: 2 fullname: Almeida, Luis, MD, PhD, FFPM – sequence: 3 fullname: Falcão, Amilcar, PharmD, PhD – sequence: 4 fullname: Soares, Eva, BSc – sequence: 5 fullname: Maia, Joana, PharmD – sequence: 6 fullname: Nunes, Teresa, MD – sequence: 7 fullname: Soares-da-Silva, Patricio, MD, PhD |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22447942$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/20171423$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkttu1DAQhiNURNuFVwBLCHHTLHZO3twgVVU5SJW4ACTurIk96XrrOMFOQOHpeDQm7LKVeoU0UpTf3_wez8x5cuJ7j0nyQvC14KJ6s1trZ_24xQDrjJPKBUXxKDkTG1mnQhTfTpIzUuo0q8XmNDmPccc5z-sye5KcUooURZafJb-v2xb1yPqWYXRWQ2jgFw7WIwONI4zIes_oIhZHBDOn8a82bCF0oPs7AkerIwNvjqKZPXSLSKY_IbQQrGcUWwQ3bmcWp2ZHd0ZmJjq5ZUD-AXGxvsUL1g_oUwcNugvWTW60g8PU9JGOIuH0M2CwvaGKJjM_TR634CI-O3xXydd311-uPqQ3n95_vLq8SXWZZ2Pamg1mYIqqlNDk1DEDpRTlphRCciOqBrhpq6bNsJJNVRR5oesmQ5FtKlPJQuar5PXedwj99wnjqDobNToHHvspKpnnpZB5WRH58gG566fgqTgleJ6LSnBeEyX3lA59jAFbNQTbQZgJUsuM1U4dZ6yWGSsuKArKfH7wn5oOzTHv31AJeHUAIGpwbQCvbbznsqKQNYGr5HLPIfXth8WgorboNRobaD7K9PY_inn7wGPhaI_cHc4Y71-uYqa4-rys5LKR1APORVnnfwDvzONV |
| CitedBy_id | crossref_primary_10_1016_j_molcatb_2011_07_004 crossref_primary_10_1080_14656566_2020_1843636 crossref_primary_10_1111_epi_12192 crossref_primary_10_1080_17425255_2020_1806236 crossref_primary_10_2165_11594640_000000000_00000 crossref_primary_10_1684_epd_2014_0714 crossref_primary_10_4137_JCNSD_S4888 crossref_primary_10_1016_j_redare_2018_04_007 crossref_primary_10_1080_14656566_2016_1182984 crossref_primary_10_1016_j_jpain_2017_08_001 crossref_primary_10_1007_s40268_017_0197_5 crossref_primary_10_1016_j_yebeh_2015_05_036 crossref_primary_10_1007_s40265_016_0570_7 crossref_primary_10_1111_j_1528_1167_2012_03519_x crossref_primary_10_1517_14656566_2012_667803 crossref_primary_10_1016_j_redar_2018_01_012 crossref_primary_10_1007_s40263_014_0182_2 crossref_primary_10_1586_ern_11_158 crossref_primary_10_1097_WCO_0b013e32834479a7 crossref_primary_10_1007_s00228_011_1114_4 crossref_primary_10_1016_j_eplepsyres_2011_05_013 crossref_primary_10_1016_j_reprotox_2011_07_001 crossref_primary_10_35615_epilia_2022_00375 crossref_primary_10_1007_s40262_013_0088_z crossref_primary_10_1517_17425255_2015_1021686 |
| Cites_doi | 10.1111/j.1528-1167.2008.01946.x 10.1177/0091270004267591 10.1097/MBC.0b013e3280444bfd 10.1007/s00228-006-0104-4 10.1002/j.1875-9114.1997.tb03782.x 10.1021/js9600134 10.1002/cpt1971123539 10.1097/00007611-199008000-00033 10.1136/bmj.280.6229.1415-a 10.2165/00126839-200304050-00001 10.1177/0091270004271404 10.2165/00126839-200506040-00002 10.1007/s00228-007-0414-1 10.1016/0006-2952(94)90071-X 10.1378/chest.119.1_suppl.22S 10.1002/ana.410130629 10.1007/BF01065653 10.1002/cpt1976195part1552 10.2165/00002018-199309030-00003 10.1038/clpt.1994.139 10.1177/0091270005279364 10.7326/0003-4819-94-2-280_1 10.2165/00126839-200506050-00001 10.1016/S0731-7085(00)00232-6 10.1016/j.nurt.2006.10.005 10.1111/j.1528-1167.2007.00984.x 10.1592/phco.21.2.235.34106 |
| ContentType | Journal Article |
| Copyright | Excerpta Medica Inc. 2010 Excerpta Medica Inc. 2015 INIST-CNRS |
| Copyright_xml | – notice: Excerpta Medica Inc. – notice: 2010 Excerpta Medica Inc. – notice: 2015 INIST-CNRS |
| DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7RV 7X7 7XB 88C 88E 8AO 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH K9. KB0 M0S M0T M1P M2O M7N MBDVC NAPCQ PQEST PQQKQ PQUKI PRINS Q9U 7X8 |
| DOI | 10.1016/j.clinthera.2010.01.014 |
| DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) Healthcare Administration Database PML(ProQuest Medical Library) Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Research Library (Corporate) Nursing & Allied Health Premium ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Research Library Prep ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College Research Library (Alumni Edition) ProQuest Pharma Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest Research Library ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Research Library Prep MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1879-114X |
| EndPage | 192 |
| ExternalDocumentID | 2734245541 10_1016_j_clinthera_2010_01_014 20171423 22447942 S0149291810000159 1_s2_0_S0149291810000159 |
| Genre | Clinical Trial Journal Article |
| GeographicLocations | Portugal |
| GeographicLocations_xml | – name: Portugal |
| GroupedDBID | - 0R 0SF 1 1- 123 1B1 1P 1~. 1~5 29B 3V. 4.4 457 4G. 53G 5RE 5VS 6J9 6PF 7-5 71M 7RV 7X7 88E 8AO 8FI 8FJ 8G5 8P AABNK AACTN AAEDT AAIAV AAIKJ AAKOC AALMO AALRI AAOAW AAPBV AAQFI AAQQT AAQXK AATCM AAWTL AAXUO AAYOK ABBQC ABFLS ABFNM ABFRF ABLVK ABMAC ABMZM ABPIF ABPTK ABQIS ABUWG ABXDB ABYKQ ABZDS ACDAQ ACPRK ACRLP ADALY ADBBV ADEZE ADFRT AEBSH AEFWE AEKER AENEX AEVXI AFCTW AFFNX AFKRA AFKWA AFRAH AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHMBA AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AQUVI ASPBG AVWKF AZFZN AZQEC BBAFP BENPR BKEYQ BKOJK BLXMC BNPGV BPHCQ BVXVI CS3 DU5 DWQXO EBS EFJIC EJD EMOBN EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FO FYUFA G- G-Q GBLVA GJ GNUQQ GUQSH HVGLF HZ H~9 IHE IPNFZ J1W K KOM LCYCR M M0T M1P M2O M41 MO0 N9A NAPCQ NCXOZ O-L O9- OAUVE OD OGGZJ OO0 OZT P-8 P-9 PADUT PC. PQEST PQQKQ PQUKI PRINS PROAC PSQYO Q38 R2- RIG ROL RPZ SCC SDF SDG SEL SES SEW SPCBC SSH SSP SSZ SV3 T5K UHS WH7 WOW Z5R ZGI ZXP --- --K --M .1- .FO .GJ .~1 0R~ 1P~ 8P~ AAEDW ABJNI ADMUD AXJTR CCPQU EFLBG FYGXN HMCUK HZ~ OD~ UKHRP XOL ~G- AKALU IQODW AAXKI ADVLN AFJKZ AKRWK ALIPV CGR CUY CVF ECM EIF NPM AAYXX CITATION 7XB 8FK K9. M7N MBDVC Q9U 7X8 |
| ID | FETCH-LOGICAL-c532t-fd8e2ad4657ab3010da5715851170d16ba0df6bf2e67b64434c9b2e1286d67473 |
| IEDL.DBID | BENPR |
| ISSN | 0149-2918 |
| IngestDate | Fri Aug 16 05:25:33 EDT 2024 Fri Sep 13 10:27:03 EDT 2024 Thu Sep 26 19:37:27 EDT 2024 Sat Sep 28 07:46:47 EDT 2024 Sun Oct 22 16:06:32 EDT 2023 Fri Feb 23 02:23:25 EST 2024 Thu Aug 18 18:35:44 EDT 2022 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | pharmacokinetics eslicarbazepine acetate drug interaction pharmacodynamics warfarin Human Pharmacokinetic pharmacodynamic relationship Warfarin Pharmacodynamics Healthy subject Coumarine derivatives Single dose Anticoagulant Anticonvulsant Eslicarbazepine Acetate Biological activity Multiple dose Antivitamin K Clinical stage Drug interaction Sodium channel blocker Pharmacokinetics |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c532t-fd8e2ad4657ab3010da5715851170d16ba0df6bf2e67b64434c9b2e1286d67473 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| OpenAccessLink | https://estudogeral.uc.pt/bitstream/10316/2809/1/AES%20Proceedings%20-%20Epilepsia%2c%2046%28Suppl.%208%29%2c%201-3%20A.pdf |
| PMID | 20171423 |
| PQID | 1033161009 |
| PQPubID | 1226358 |
| PageCount | 14 |
| ParticipantIDs | proquest_miscellaneous_733517356 proquest_journals_1033161009 crossref_primary_10_1016_j_clinthera_2010_01_014 pubmed_primary_20171423 pascalfrancis_primary_22447942 elsevier_sciencedirect_doi_10_1016_j_clinthera_2010_01_014 elsevier_clinicalkeyesjournals_1_s2_0_S0149291810000159 |
| PublicationCentury | 2000 |
| PublicationDate | 2010 2010-Jan 2010-1-00 20100101 |
| PublicationDateYYYYMMDD | 2010-01-01 |
| PublicationDate_xml | – year: 2010 text: 2010 |
| PublicationDecade | 2010 |
| PublicationPlace | Bridgewater, NJ |
| PublicationPlace_xml | – name: Bridgewater, NJ – name: United States – name: Bridgewater |
| PublicationTitle | Clinical therapeutics |
| PublicationTitleAlternate | Clin Ther |
| PublicationYear | 2010 |
| Publisher | EM Inc USA Elsevier Elsevier Limited |
| Publisher_xml | – name: EM Inc USA – name: Elsevier – name: Elsevier Limited |
| References | Chan, McLachlan, O’Reilly, Rowland (bib8) 1994; 56 Redman (bib10) 2001; 21 Almeida, Soares-da-Silva (bib22) 2003; 4 Kerr, Thummel, Wurden (bib18) 1994; 47 Massey (bib16) 1983; 13 Almeida, Soares-da-Silva (bib5) 2007; 4 Lopes-Lima, Gil-Nagel, Maia (bib3) 2009; 50 Osman, Enström, Lindahl (bib35) 2007; 18 Denbow, Fraser (bib17) 1990; 83 bib29 Steinijans, Sauter, Hauschke (bib31) 1995; 33 bib28 Hansen, Siersboek-Nielsen, Skovsted (bib13) 1971; 12 Elger, Bialer, Cramer (bib6) 2007; 48 Ross, Beeley (bib14) 1980; 280 Maia, Vaz-da-Silva, Almeida (bib25) 2005; 6 Kendall, Boivin (bib15) 1981; 94 Almeida, Soares-da-Silva (bib23) 2004; 44 Patsalos, Duncan (bib12) 1993; 9 bib26 Almeida, Potgieter, Maia (bib33) 2008; 64 bib21 Mungall, Ludden, Marshall (bib30) 1985; 13 He, Shibukawa, Tokunaga, Nakagawa (bib34) 1997; 86 Almeida, Falcão, Maia (bib4) 2005; 45 bib20 Cropp, Bussey (bib11) 1997; 17 Fontes-Ribeiro, Nunes, Falcão (bib24) 2005; 6 Ansell, Hirsh, Dalen (bib7) 2001; 119 Greenblatt, von Moltke (bib32) 2005; 45 Hufnagel, Ben-Menachem, Gabbai (bib2) 2009; 50 Yacobi, Udall, Levy (bib9) 1976; 19 Herman, Locatelli, Grabnar (bib19) 2006; 62 Ring, Bostick (bib27) 2000; 22 Elger, Halász, Maia (bib1) 2009; 50 He (10.1016/j.clinthera.2010.01.014_bib34) 1997; 86 Fontes-Ribeiro (10.1016/j.clinthera.2010.01.014_bib24) 2005; 6 Almeida (10.1016/j.clinthera.2010.01.014_bib33) 2008; 64 Chan (10.1016/j.clinthera.2010.01.014_bib8) 1994; 56 Kendall (10.1016/j.clinthera.2010.01.014_bib15) 1981; 94 Yacobi (10.1016/j.clinthera.2010.01.014_bib9) 1976; 19 Ross (10.1016/j.clinthera.2010.01.014_bib14) 1980; 280 Almeida (10.1016/j.clinthera.2010.01.014_bib23) 2004; 44 Mungall (10.1016/j.clinthera.2010.01.014_bib30) 1985; 13 Almeida (10.1016/j.clinthera.2010.01.014_bib5) 2007; 4 Massey (10.1016/j.clinthera.2010.01.014_bib16) 1983; 13 Patsalos (10.1016/j.clinthera.2010.01.014_bib12) 1993; 9 Denbow (10.1016/j.clinthera.2010.01.014_bib17) 1990; 83 Elger (10.1016/j.clinthera.2010.01.014_bib6) 2007; 48 Redman (10.1016/j.clinthera.2010.01.014_bib10) 2001; 21 Greenblatt (10.1016/j.clinthera.2010.01.014_bib32) 2005; 45 Ansell (10.1016/j.clinthera.2010.01.014_bib7) 2001; 119 Elger (10.1016/j.clinthera.2010.01.014_bib1) 2009; 50 Ring (10.1016/j.clinthera.2010.01.014_bib27) 2000; 22 Osman (10.1016/j.clinthera.2010.01.014_bib35) 2007; 18 Hansen (10.1016/j.clinthera.2010.01.014_bib13) 1971; 12 Maia (10.1016/j.clinthera.2010.01.014_bib25) 2005; 6 Herman (10.1016/j.clinthera.2010.01.014_bib19) 2006; 62 Kerr (10.1016/j.clinthera.2010.01.014_bib18) 1994; 47 Hufnagel (10.1016/j.clinthera.2010.01.014_bib2) 2009; 50 Lopes-Lima (10.1016/j.clinthera.2010.01.014_bib3) 2009; 50 Steinijans (10.1016/j.clinthera.2010.01.014_bib31) 1995; 33 Almeida (10.1016/j.clinthera.2010.01.014_bib4) 2005; 45 Cropp (10.1016/j.clinthera.2010.01.014_bib11) 1997; 17 Almeida (10.1016/j.clinthera.2010.01.014_bib22) 2003; 4 |
| References_xml | – volume: 22 start-page: 573 year: 2000 end-page: 581 ident: bib27 article-title: Validation of a method for the determination of (R)-warfarin and (S)-warfarin in human plasma using LC with UV detection publication-title: J Pharm Biomed Anal. contributor: fullname: Bostick – volume: 4 start-page: 269 year: 2003 end-page: 284 ident: bib22 article-title: Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans publication-title: Drugs R D. contributor: fullname: Soares-da-Silva – volume: 50 start-page: 454 year: 2009 end-page: 463 ident: bib1 article-title: Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized, doubleblind, placebo-controlled, parallel-group phase III study publication-title: Epilepsia. contributor: fullname: Maia – volume: 19 start-page: 552 year: 1976 end-page: 558 ident: bib9 article-title: Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect publication-title: Clin Pharmacol Ther. contributor: fullname: Levy – ident: bib28 article-title: Note for guidance on the investigation of bioavailability and bioequivalence – volume: 13 start-page: 691 year: 1983 end-page: 692 ident: bib16 article-title: Effect of carbamazepine on Coumadin metabolism publication-title: Ann Neurol. contributor: fullname: Massey – volume: 33 start-page: 427 year: 1995 end-page: 430 ident: bib31 article-title: Reference tables for the intrasubject coefficient of variation in bioequivalence studies publication-title: Int J Clin Pharmacol Ther. contributor: fullname: Hauschke – volume: 45 start-page: 1062 year: 2005 end-page: 1066 ident: bib4 article-title: Single-dose and steadystate pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects publication-title: J Clin Pharmacol. contributor: fullname: Maia – volume: 50 start-page: 104 year: 2009 ident: bib2 article-title: Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-302 study publication-title: Epilepsia. contributor: fullname: Gabbai – volume: 21 start-page: 235 year: 2001 end-page: 242 ident: bib10 article-title: Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing publication-title: Pharmacotherapy. contributor: fullname: Redman – volume: 6 start-page: 201 year: 2005 end-page: 206 ident: bib25 article-title: Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093) publication-title: Drugs R D. contributor: fullname: Almeida – volume: 6 start-page: 253 year: 2005 end-page: 260 ident: bib24 article-title: Eslicarbazepine acetate (BIA 2-093): Relative bioavailability and bioequivalence of 50 mg/mL oral suspension and 200mg and 800mg tablet formulations publication-title: Drugs R D. contributor: fullname: Falcão – volume: 12 start-page: 539 year: 1971 end-page: 543 ident: bib13 article-title: Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man publication-title: Clin Pharmacol Ther. contributor: fullname: Skovsted – volume: 48 start-page: 497 year: 2007 end-page: 504 ident: bib6 article-title: Eslicarbazepine acetate: A doubleblind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures publication-title: Epilepsia. contributor: fullname: Cramer – volume: 62 start-page: 291 year: 2006 end-page: 296 ident: bib19 article-title: The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose publication-title: Eur J Clin Pharmacol. contributor: fullname: Grabnar – ident: bib29 article-title: Note for guidance on the investigation of drug interactions – volume: 45 start-page: 127 year: 2005 end-page: 132 ident: bib32 article-title: Interaction of warfarin with drugs, natural substances, and foods publication-title: J Clin Pharmacol. contributor: fullname: von Moltke – ident: bib26 article-title: Coumadin (warfarin sodium) crystalline has been helping to protect appropriate patients for over 50 years – volume: 9 start-page: 156 year: 1993 end-page: 184 ident: bib12 article-title: Antiepileptic drugs. A review of clinically significant drug interactions publication-title: Drug Saf. contributor: fullname: Duncan – volume: 56 start-page: 286 year: 1994 end-page: 294 ident: bib8 article-title: Stereochemical aspects of warfarin drug interactions: Use of a combined pharmacokineticpharmacodynamic model publication-title: Clin Pharmacol Ther. contributor: fullname: Rowland – ident: bib21 article-title: Good Clinical Practice (GCP), topic E6, step 5, March 1997 – volume: 280 start-page: 1415 year: 1980 end-page: 1416 ident: bib14 article-title: Interaction between carbamazepine and warfarin publication-title: Br MedJ. contributor: fullname: Beeley – volume: 94 start-page: 280 year: 1981 ident: bib15 article-title: Warfarincarbamazepine interaction publication-title: Ann Intern Med. contributor: fullname: Boivin – volume: 44 start-page: 906 year: 2004 end-page: 918 ident: bib23 article-title: Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multipledose study in young healthy humans publication-title: J Clin Pharmacol. contributor: fullname: Soares-da-Silva – volume: 13 start-page: 213 year: 1985 end-page: 227 ident: bib30 article-title: Population pharmacokinetics of racemic warfarin in adult patients publication-title: J Pharmacokinet Biopharm. contributor: fullname: Marshall – volume: 83 start-page: 981 year: 1990 ident: bib17 article-title: Clinically significant hemorrhage due to war- farin-carbamazepine interaction publication-title: South MedJ. contributor: fullname: Fraser – ident: bib20 article-title: Declaration of Helsinki: Ethical principles for medical research involving human subjects – volume: 50 start-page: 106 year: 2009 ident: bib3 article-title: Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-303 study publication-title: Epilepsia. contributor: fullname: Maia – volume: 4 start-page: 88 year: 2007 end-page: 96 ident: bib5 article-title: Eslicarbazepine acetate (BIA 2-093) publication-title: Neurotherapeutics. contributor: fullname: Soares-da-Silva – volume: 119 start-page: 22S year: 2001 end-page: 38S ident: bib7 article-title: Managing oral anticoagulant therapy publication-title: Chest. contributor: fullname: Dalen – volume: 18 start-page: 293 year: 2007 end-page: 296 ident: bib35 article-title: Plasma S/R ratio of warfarin covaries with VKORC1 haplotype publication-title: Blood Coagul Fibrinolysis. contributor: fullname: Lindahl – volume: 17 start-page: 917 year: 1997 end-page: 928 ident: bib11 article-title: A review of enzyme induction of warfarin metabolism with recommendations for patient management publication-title: Pharmacotherapy. contributor: fullname: Bussey – volume: 64 start-page: 267 year: 2008 end-page: 273 ident: bib33 article-title: Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment publication-title: Eur J Clin Pharmacol. contributor: fullname: Maia – volume: 47 start-page: 1969 year: 1994 end-page: 1979 ident: bib18 article-title: Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation publication-title: Biochem Pharmacol. contributor: fullname: Wurden – volume: 86 start-page: 120 year: 1997 end-page: 125 ident: bib34 article-title: Protein-binding highperformance frontal analysis of (R)-and (S)-warfarin on HSA with and without phenylbutazone publication-title: J Pharm Sci. contributor: fullname: Nakagawa – volume: 50 start-page: 454 year: 2009 ident: 10.1016/j.clinthera.2010.01.014_bib1 article-title: Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized, doubleblind, placebo-controlled, parallel-group phase III study publication-title: Epilepsia. doi: 10.1111/j.1528-1167.2008.01946.x contributor: fullname: Elger – volume: 44 start-page: 906 year: 2004 ident: 10.1016/j.clinthera.2010.01.014_bib23 article-title: Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multipledose study in young healthy humans publication-title: J Clin Pharmacol. doi: 10.1177/0091270004267591 contributor: fullname: Almeida – volume: 18 start-page: 293 year: 2007 ident: 10.1016/j.clinthera.2010.01.014_bib35 article-title: Plasma S/R ratio of warfarin covaries with VKORC1 haplotype publication-title: Blood Coagul Fibrinolysis. doi: 10.1097/MBC.0b013e3280444bfd contributor: fullname: Osman – volume: 62 start-page: 291 year: 2006 ident: 10.1016/j.clinthera.2010.01.014_bib19 article-title: The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose publication-title: Eur J Clin Pharmacol. doi: 10.1007/s00228-006-0104-4 contributor: fullname: Herman – volume: 50 start-page: 104 issue: Suppl 4 year: 2009 ident: 10.1016/j.clinthera.2010.01.014_bib2 article-title: Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-302 study publication-title: Epilepsia. contributor: fullname: Hufnagel – volume: 17 start-page: 917 year: 1997 ident: 10.1016/j.clinthera.2010.01.014_bib11 article-title: A review of enzyme induction of warfarin metabolism with recommendations for patient management publication-title: Pharmacotherapy. doi: 10.1002/j.1875-9114.1997.tb03782.x contributor: fullname: Cropp – volume: 86 start-page: 120 year: 1997 ident: 10.1016/j.clinthera.2010.01.014_bib34 article-title: Protein-binding highperformance frontal analysis of (R)-and (S)-warfarin on HSA with and without phenylbutazone publication-title: J Pharm Sci. doi: 10.1021/js9600134 contributor: fullname: He – volume: 12 start-page: 539 year: 1971 ident: 10.1016/j.clinthera.2010.01.014_bib13 article-title: Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man publication-title: Clin Pharmacol Ther. doi: 10.1002/cpt1971123539 contributor: fullname: Hansen – volume: 83 start-page: 981 year: 1990 ident: 10.1016/j.clinthera.2010.01.014_bib17 article-title: Clinically significant hemorrhage due to war- farin-carbamazepine interaction publication-title: South MedJ. doi: 10.1097/00007611-199008000-00033 contributor: fullname: Denbow – volume: 280 start-page: 1415 year: 1980 ident: 10.1016/j.clinthera.2010.01.014_bib14 article-title: Interaction between carbamazepine and warfarin publication-title: Br MedJ. doi: 10.1136/bmj.280.6229.1415-a contributor: fullname: Ross – volume: 4 start-page: 269 year: 2003 ident: 10.1016/j.clinthera.2010.01.014_bib22 article-title: Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans publication-title: Drugs R D. doi: 10.2165/00126839-200304050-00001 contributor: fullname: Almeida – volume: 45 start-page: 127 year: 2005 ident: 10.1016/j.clinthera.2010.01.014_bib32 article-title: Interaction of warfarin with drugs, natural substances, and foods publication-title: J Clin Pharmacol. doi: 10.1177/0091270004271404 contributor: fullname: Greenblatt – volume: 6 start-page: 201 year: 2005 ident: 10.1016/j.clinthera.2010.01.014_bib25 article-title: Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093) publication-title: Drugs R D. doi: 10.2165/00126839-200506040-00002 contributor: fullname: Maia – volume: 64 start-page: 267 year: 2008 ident: 10.1016/j.clinthera.2010.01.014_bib33 article-title: Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment publication-title: Eur J Clin Pharmacol. doi: 10.1007/s00228-007-0414-1 contributor: fullname: Almeida – volume: 47 start-page: 1969 year: 1994 ident: 10.1016/j.clinthera.2010.01.014_bib18 article-title: Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation publication-title: Biochem Pharmacol. doi: 10.1016/0006-2952(94)90071-X contributor: fullname: Kerr – volume: 119 start-page: 22S issue: Suppl year: 2001 ident: 10.1016/j.clinthera.2010.01.014_bib7 article-title: Managing oral anticoagulant therapy publication-title: Chest. doi: 10.1378/chest.119.1_suppl.22S contributor: fullname: Ansell – volume: 13 start-page: 691 year: 1983 ident: 10.1016/j.clinthera.2010.01.014_bib16 article-title: Effect of carbamazepine on Coumadin metabolism publication-title: Ann Neurol. doi: 10.1002/ana.410130629 contributor: fullname: Massey – volume: 13 start-page: 213 year: 1985 ident: 10.1016/j.clinthera.2010.01.014_bib30 article-title: Population pharmacokinetics of racemic warfarin in adult patients publication-title: J Pharmacokinet Biopharm. doi: 10.1007/BF01065653 contributor: fullname: Mungall – volume: 19 start-page: 552 year: 1976 ident: 10.1016/j.clinthera.2010.01.014_bib9 article-title: Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect publication-title: Clin Pharmacol Ther. doi: 10.1002/cpt1976195part1552 contributor: fullname: Yacobi – volume: 9 start-page: 156 year: 1993 ident: 10.1016/j.clinthera.2010.01.014_bib12 article-title: Antiepileptic drugs. A review of clinically significant drug interactions publication-title: Drug Saf. doi: 10.2165/00002018-199309030-00003 contributor: fullname: Patsalos – volume: 56 start-page: 286 year: 1994 ident: 10.1016/j.clinthera.2010.01.014_bib8 article-title: Stereochemical aspects of warfarin drug interactions: Use of a combined pharmacokineticpharmacodynamic model publication-title: Clin Pharmacol Ther. doi: 10.1038/clpt.1994.139 contributor: fullname: Chan – volume: 45 start-page: 1062 year: 2005 ident: 10.1016/j.clinthera.2010.01.014_bib4 article-title: Single-dose and steadystate pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects publication-title: J Clin Pharmacol. doi: 10.1177/0091270005279364 contributor: fullname: Almeida – volume: 94 start-page: 280 year: 1981 ident: 10.1016/j.clinthera.2010.01.014_bib15 article-title: Warfarincarbamazepine interaction publication-title: Ann Intern Med. doi: 10.7326/0003-4819-94-2-280_1 contributor: fullname: Kendall – volume: 50 start-page: 106 issue: Suppl 4 year: 2009 ident: 10.1016/j.clinthera.2010.01.014_bib3 article-title: Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-303 study publication-title: Epilepsia. contributor: fullname: Lopes-Lima – volume: 33 start-page: 427 year: 1995 ident: 10.1016/j.clinthera.2010.01.014_bib31 article-title: Reference tables for the intrasubject coefficient of variation in bioequivalence studies publication-title: Int J Clin Pharmacol Ther. contributor: fullname: Steinijans – volume: 6 start-page: 253 year: 2005 ident: 10.1016/j.clinthera.2010.01.014_bib24 article-title: Eslicarbazepine acetate (BIA 2-093): Relative bioavailability and bioequivalence of 50 mg/mL oral suspension and 200mg and 800mg tablet formulations publication-title: Drugs R D. doi: 10.2165/00126839-200506050-00001 contributor: fullname: Fontes-Ribeiro – volume: 22 start-page: 573 year: 2000 ident: 10.1016/j.clinthera.2010.01.014_bib27 article-title: Validation of a method for the determination of (R)-warfarin and (S)-warfarin in human plasma using LC with UV detection publication-title: J Pharm Biomed Anal. doi: 10.1016/S0731-7085(00)00232-6 contributor: fullname: Ring – volume: 4 start-page: 88 year: 2007 ident: 10.1016/j.clinthera.2010.01.014_bib5 article-title: Eslicarbazepine acetate (BIA 2-093) publication-title: Neurotherapeutics. doi: 10.1016/j.nurt.2006.10.005 contributor: fullname: Almeida – volume: 48 start-page: 497 year: 2007 ident: 10.1016/j.clinthera.2010.01.014_bib6 article-title: Eslicarbazepine acetate: A doubleblind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures publication-title: Epilepsia. doi: 10.1111/j.1528-1167.2007.00984.x contributor: fullname: Elger – volume: 21 start-page: 235 year: 2001 ident: 10.1016/j.clinthera.2010.01.014_bib10 article-title: Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing publication-title: Pharmacotherapy. doi: 10.1592/phco.21.2.235.34106 contributor: fullname: Redman |
| SSID | ssj0003952 |
| Score | 2.143168 |
| Snippet | Abstract Background: The anticoagulant warfarin, which is administered as a racemic mixture of R - and S -enantiomers, has been reported to interact with other... Background: The anticoagulant warfarin, which is administered as a racemic mixture of R- and S-enantiomers, has been reported to interact with other drugs,... The anticoagulant warfarin, which is administered as a racemic mixture of R- and S-enantiomers, has been reported to interact with other drugs, including some... Background_ The anticoagulant warfarin, which is administered as a racemic mixture of R - and S -enantiomers, has been reported to interact with other drugs,... BACKGROUNDThe anticoagulant warfarin, which is administered as a racemic mixture of R- and S-enantiomers, has been reported to interact with other drugs,... |
| SourceID | proquest crossref pubmed pascalfrancis elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 179 |
| SubjectTerms | Adult Adults Anticoagulants Anticoagulants - administration & dosage Anticoagulants - blood Anticoagulants - pharmacology Area Under Curve Bioavailability Bioequivalence Biological and medical sciences Blood Coagulation - drug effects Chromatography, High Pressure Liquid - methods Convulsions & seizures Delayed-Action Preparations Dibenzazepines - administration & dosage Dibenzazepines - pharmacology Dose-Response Relationship, Drug Drug dosages drug interaction Drug interactions Drug therapy eslicarbazepine acetate Female Humans Internal Medicine International Normalized Ratio Male Medical Education Medical sciences Metabolism pharmacodynamics Pharmacokinetics Pharmacology. Drug treatments R&D Research & development Sodium Channel Blockers - administration & dosage Sodium Channel Blockers - pharmacology Tandem Mass Spectrometry - methods Time Factors warfarin Warfarin - administration & dosage Warfarin - blood Warfarin - pharmacology Young Adult |
| SummonAdditionalLinks | – databaseName: ScienceDirect Freedom Collection 2023 dbid: AIKHN link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9swEBddCmNQxtZ9eeuKHkafImJbH473VspKtrHShxb6JuRIGu2GHaKEkv11-9N2Z9kOYZQ9DPRiSz7L9vnudPrdHSEfpDG8FGbKRJ7PmaisZKWXnlUe1IGbO1iUtGiLCzW7Fl9u5M0eOetjYRBW2cn-KNNbad2dmXRvc7K4vZ0gLAl0O2io1kMty0dkH9SRECOyf_r56-xiEMi8bAvv4HiGF-zAvDAAsQ116mBeGTTxkJI6WJgAr87HmhcPG6Wtcjp_Rp52ViU9jRN_TvZcfUgef-v2zQ_JyWXMUL0Z06ttwFUY0xN6uc1dvXlBfsdsxrTx1AX05y0r88stgAg1c0QmOtrUFJ6EttyxYW1AEl10RH7AQCRMTW2HkzYWvQ9I9N4sPazOawothmBuaFhX6AwKNIZMUgP0l84h6e9uTLG-FwNedT_HtIc_MtsE6EI_BxxgsubG0jZT7ktyff7p6mzGuiIPbC55vmLeTl1urFCyMBVIm9QaWWS4WZkVqc1UZVLrVeVzp4oKjDcu5mWVO1CryipYC_FXZFQ3tXtDaJ5ZGCWy0jsvlJpOFeb-n3ovVcmt4glJ-6-qFzGXh-5Bbnd6YASNjKDTDJpISNF_fd2HqoJwdaH704POdMh1qv_ixoR8HK7cYWgNuurftz3e4bRhumBwYUmAPCFHPevp7VRSzsGAB6s5IXToBnGBe0Cmds066IJzmRVcqoS8jhy7pY2pk8C6fvs_M39HnkR8BTqpjshotVy792C2rarj7rf8A1CzRHU priority: 102 providerName: Elsevier |
| Title | Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study |
| URI | https://www.clinicalkey.es/playcontent/1-s2.0-S0149291810000159 https://dx.doi.org/10.1016/j.clinthera.2010.01.014 https://www.ncbi.nlm.nih.gov/pubmed/20171423 https://www.proquest.com/docview/1033161009/abstract/ https://search.proquest.com/docview/733517356 |
| Volume | 32 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3da9swEBdtA2NQxtZ91FsX9DD6FK2WZcv2XkY3WrKNhTBayJuQLamwDTuLE0b2sL9tf9ruLNuhD91ABBzbZyU-3f10n4S8SrQWeawzFkdRyeLCJCx3iWOFA3VgSwubkjbaYian1_HHRbLYI9M-FwbDKnuZ2ApqU5doI4fVLQSgE4AEZ7pAK0C5Pnu7_MGwfxT6WbtmGvtkFPEYHbajdxez-ZdBKou87b6DOwIW5Ty7FeuFWYhtvlMX68VhxHdpqsOlbuD_c77xxd3ItNVQlw_Jgw5a0nPPC4_Inq2OyL3PnfP8iJzOfZnq7YRe7bKumgk9pfNdAevtY_LHlzSmtaO2QaPeqtC_7BKIUF1ieKKldUXhl9CWRbaszUqiy47IN7gQCVNdmeFL4zvfN0j0p1452KJXFIbPw9zSZlOgRaihPm-SaqC_shZJ39gJxSZfDBjWfp_QPgaSmbqBU2jsgAOs2Fwb2pbLfUKuLy-u3k9Z1-mBlYmI1syZzEbaxDJJdQEiJzQ6STl6LHkaGi4LHRonCxdZmRaA4ERc5kVkQbdKI2FDJJ6Sg6qu7DGhETdwVcxzZ10sZZZJbACQOZfIXBgpAhL2b1UtfUEP1Ue6fVUDIyhkBBVyGHFA0v7tqz5fFSSsbbrl3iiumkiFbaRcjszlnSZJHpA3w50dovFIRYHC-v9jx7c4bZguoC7sCxAF5KRnPbWbyrBOAkKH0yAz0BGkK1tvGpUKkfBUJDIgzzzH7mhj_SSA2M__TfsFue_DKNAWdUIO1quNfQnobF2Myf7r3xw-00U6JqPzD5-ms3G3GP8CGkdAtQ |
| link.rule.ids | 315,786,790,4043,4521,12083,21416,24144,27956,27957,27958,31754,31755,33779,33780,43345,43840,45620,45714,74102,74659 |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1bb9MwFLagkwAJIRi3wBh-QHuqpSS-JOEFAdpUYKsqtEl7s5zYngQoKXUrVH4dP43j2Em1h4HklzTpaZocn_OdO0JvuFK0YqokLM8bwmrNSWW5JbUFdWAaA0ZJn20xF7ML9vmSX0aHm4tplYNM7AW17hrvI4fdTSmgE4AE75Y_iZ8a5aOrcYTGbbTHKJgqE7T34Xi--DrKYlr1M3e8HUDyKiuvZXj52sO-yilmeGWw2E366f5SOXhqNoy7uBmP9nrp5CF6EAElfh844BG6Zdp9dOcshsz30dEiNKfeTvH5rtbKTfERXuzaVm8foz-hkTHuLDbOu_JWtfptlkAEq8YnJRrctRj-Ce4ZY0v6WiS8jES-w4WeMFatHj_UYd6980R_qZUFw7zFsEL15Ra7Te39QA6HakmsgP7KGE_6ykyxH-1FgE3NjykeMh-J7hyc8i4OOPB9mjuN-ya5T9DFyfH5xxmJ8x1Iw2m-JlaXJleaCV6oGgRNqhUvMh-nzIpUZ6JWqbaitrkRRQ24jbKmqnMDGlVoAWYQfYombdea5wjnmYarWFZZY5kQZSl82__SWi4qqgVNUDq8VbkMbTzkkN_2TY6MID0jyDSDxRJUDG9fDlWqIFeNi5vcyUy6XKZ9flzlmSuESniVoLfjNyOOCfhEgpr6_88eXuO08XYBa_lpAHmCDgbWk7tbGXdHgvB4GiSFD_-o1nQbJwtKeVZQLhL0LHDsjrbvmgTA-sW_ab9Gd2fnZ6fy9NP8y0t0LyRSeG_UAZqsVxvzCvDZuj6Mm_Avda48dQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwELagSBUSQlBegVJ8QD2tRRLHTsIFIaAqr2oPrbQ3y4ntSoCSZb0rtPw6fhozsZNVDwXJl2yys9lkxvP6ZoaQl0JrXhe6YkWet6xojGC1E441DtSBbS04JQPa4kyeXhSfFmIR8U8-wirHPXHYqE3fYowcpJtzsE7AJHjlIixi_v7kzfInwwlSmGmN4zRuklugJVOcZlAuJucr5fUwfQc9ApbXWXUF64VViEO9U8R6ZbCK6zTVnaX28PxcGHxxvWU6aKiTe-RuNC3p28AL98kN2x2Q_a8xeX5AjuehTfV2Rs93VVd-Ro_pfNfAevuA_AktjWnvqPUY1Fs1-rddAhGqW4QnWtp3FP4JHVhky4aqJLqMRL7DhUiY6s5MH5ow-d4j0V965cBF7yisUIe5pX7TYETI01A3STXQX1mLpC_tjOKQLwYMa3_M6IiBZKb3cAqDHXCAHZt7Q4d2uQ_JxcmH83enLE56YK3g-Zo5U9lcm0KKUjew5aRGizLDjGVWpiaTjU6Nk43LrSwbsOB40dZNbkG3SiPBIeKPyF7Xd_YJoXlm4Koiq511hZRVJXEAQOWckDU3kickHd-qWoaGHmpEun1TEyMoZASVZrCKhJTj21djvSrssNZHcfcqUz5X6YCUq5G5QtJE1Al5PX0zWjTBUlGgsP7_s0dXOG26XbC6cC5AnpDDkfXU7lYmOUkInU7DnoGJIN3ZfuNVybnISi5kQh4Hjt3Rxv5JYGI__TftF2QfpE99-Xj2-Rm5HRAVGJY6JHvr1cY-B0Nt3RwNEvgX4vU_Ow |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+eslicarbazepine+acetate+on+the+steady-state+pharmacokinetics+and+pharmacodynamics+of+warfarin+in+healthy+subjects+during+a+three-stage%2C+open-label%2C+multiple-dose%2C+single-period+study&rft.jtitle=Clinical+therapeutics&rft.au=Vaz-da-Silva%2C+Manuel%2C+MD%2C+PhD&rft.au=Almeida%2C+Luis%2C+MD%2C+PhD%2C+FFPM&rft.au=Falc%C3%A3o%2C+Amilcar%2C+PharmD%2C+PhD&rft.au=Soares%2C+Eva%2C+BSc&rft.date=2010&rft.issn=0149-2918&rft.eissn=1879-114X&rft.volume=32&rft.issue=1&rft.spage=179&rft.epage=192&rft_id=info:doi/10.1016%2Fj.clinthera.2010.01.014&rft.externalDocID=1_s2_0_S0149291810000159 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01492918%2FS0149291810X00030%2Fcov150h.gif |